Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02776683 · ClinicalTrials.gov registry record · Phase 3
Open-label, Single Arm Trial of BI 695502 in Patients With Previously Untreated Metastatic Colorectal Cancer
A Phase 3 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 3
- Development phase
- 123
- Enrollment target
NCT02776683 is a Phase 3 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 123 participants.
The verdict
NCT02776683, a Phase 3 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 123 participants
- Enrollment target
Study Summary
The objective of this trial is to evaluate the safety and tolerability of BI 695502 in combination with leucovorin/5-fluorouracil/oxaliplatin (mFOLFOX6) and as maintenance therapy (when applicable). As well as to evaluate the following efficacy parameters: Progression-free survival (PFS), objective response rate (proportion of patients with complete response \[CR\] plus partial response \[PR\]), overall survival (OS), duration of response (DOR), time to progression (TTP).
Interventions
- DRUG Avastin
- DRUG BI 695502
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 123 participants |
| Start Date | 2016-06-08 |
| Est. Completion | 2018-10-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02776683
The ClinicalTrials.gov registry entry for NCT02776683 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 123 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Avastin is the first listed.
NCT02776683 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02776683 about?
NCT02776683 is a clinical study titled "Open-label, Single Arm Trial of BI 695502 in Patients With Previously Untreated Metastatic Colorectal Cancer". The objective of this trial is to evaluate the safety and tolerability of BI 695502 in combination with leucovorin/5-fluorouracil/oxaliplatin (mFOLFOX6) and as maintenance therapy (when applicable). As well as to evaluate the following efficacy parameters: Progression-free survival (PFS), objective ...
What is the current status of trial NCT02776683?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 123 participants. The study started on 2016-06-08. Estimated completion is 2018-10-03.
What interventions are being tested in trial NCT02776683?
The interventions under investigation include: Avastin (DRUG), BI 695502 (DRUG).
Who is sponsoring clinical trial NCT02776683?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.